Firebrick Pharma Limited (AU:FRE)
ASX:FRE
Want to see AU:FRE full AI Analyst Report?
FRE Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.09
Previous CloseN/A
Volume87.61K
Average Volume (3M)91.61K
Market Cap
AU$11.39M
Enterprise ValueAU$8.13M
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.57
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,978,970
10 Day Avg. Volume136,612
30 Day Avg. Volume91,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.38
Price to Sales (P/S)44.43
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Zero DebtZero reported debt and a 0 debt-to-equity ratio materially reduce solvency and refinancing risk. For a small pharma developer, low leverage provides durable financial flexibility to fund R&D, pursue partnerships, or survive development cycles without immediate debt pressure.
Positive Gross Margin (product Economics)A ~36% gross margin indicates the company's core product or commercial activities can cover direct costs. If revenue stabilises, this durable margin can deliver operating leverage and support scalable profitability as fixed R&D and SG&A are absorbed.
Reduced Cash Burn Trend Versus Prior YearsA meaningful reduction in cash burn versus 2023 suggests management has improved cost control or reprioritised spending. This sustained downward trend in outflows lengthens runway and is a durable operational improvement for a small, cash-constrained pharma company.
Bears Say
Sharp Revenue DeclineA ~74% year-over-year revenue collapse is a material deterioration of commercial traction or recurring sales. Such durable top-line weakness undermines the firm's ability to amortise fixed costs, fund R&D internally, and maintain investor confidence without external financing.
Large Operating Losses And Deeply Negative Net MarginOperating losses and a net margin near -900% reflect losses vastly exceeding revenue, signalling the business is far from break-even. Persistent heavy losses erode equity, limit reinvestment capacity, and create ongoing pressure to secure dilutive funding.
Consistent Negative Operating And Free Cash FlowConsistently negative operating and free cash flow demonstrate the company cannot self-fund operations or growth. Persistent cash burn forces reliance on external capital, increasing dilution risk and constraining long-term strategic choices in drug development and commercialization.
Firebrick Pharma Limited News
FRE FAQ
What was Firebrick Pharma Limited’s price range in the past 12 months?
Firebrick Pharma Limited lowest share price was AU$0.04 and its highest was AU$0.09 in the past 12 months.
What is Firebrick Pharma Limited’s market cap?
Firebrick Pharma Limited’s market cap is AU$11.39M.
When is Firebrick Pharma Limited’s upcoming earnings report date?
Firebrick Pharma Limited’s upcoming earnings report date is Aug 28, 2026 which is in 98 days.
How were Firebrick Pharma Limited’s earnings last quarter?
Firebrick Pharma Limited released its earnings results on Mar 04, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Firebrick Pharma Limited overvalued?
According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued.
Does Firebrick Pharma Limited pay dividends?
Firebrick Pharma Limited does not currently pay dividends.
What is Firebrick Pharma Limited’s EPS estimate?
Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Firebrick Pharma Limited have?
Firebrick Pharma Limited has 284,978,970 shares outstanding.
What happened to Firebrick Pharma Limited’s price movement after its last earnings report?
Firebrick Pharma Limited reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of Firebrick Pharma Limited?
Currently, no hedge funds are holding shares in AU:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Firebrick Pharma Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:FRE Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$14.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.66%
12-Months-Change
Fundamentals
Return on Equity
-140.26%
Trailing 12-Months
Asset Growth
24.27%
Trailing 12-Months
Company Description
Firebrick Pharma Limited
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Technical Analysis
Hexima Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---